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Abstract This study investigated the relationship between
platelet (PLT) serotonin (5-HT) and intestinal permeability
in children with pervasive developmental disorders (PDD).
Differential sugar absorption and PLT 5-HT were deter-
mined in 23 children with PDD. PLT 5-HT (2.0–7.1 nmol/
10
9 PLT) was elevated in 4/23 patients. None exhibited
elevated intestinal permeability (lactulose/mannitol ratio:
0.008–0.035 mol/mol). PLT 5-HT did not correlate with
intestinal permeability or GI tract complaints. PLT 5-HT
correlated with 24 h urinary 5-hydroxyindoleacetic acid
(5-HIAA; p = .034). Also urinary 5-HIAA and urinary
5-HT were interrelated (p = .005). A link between hyper-
serotonemia and increased intestinal permeability remained
unsupported. Increased PLT 5-HT in PDD is likely to derive
from increased PLT exposure to 5-HT. Longitudinal stud-
ies, showing the (in)consistency of abnormal intestinal
permeability and PLT 5-HT, may resolve present discrep-
ancies in the literature.
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Introduction
Autism has been linked to gastrointestinal (GI) distur-
bances (White 2003). It is, however, questionable whether
GI anomalies in children with autism are speciﬁc (Erickson
et al., 2005). An increase of chronic diarrhea, constipation,
abdominal bloating and food regurgitation has been found
in some studies, but could not be conﬁrmed in more recent
studies (reviewed by Erickson et al. 2005). Increased GI
permeability, as established through the differential sugar
absorption test (SAT), was demonstrated in 9/21 (43%)
(D’Eufemia et al., 1996) and 19/26 (76%) (Horvath &
Perman, 2002) of patients diagnosed with autism. The SAT
measures the integrity of the intestine by the ingestion of
two indigestible saccharides that after GI uptake become
fully excreted in urine. One of these (usually lactulose)
passes the intestinal wall through paracellular transport
(‘leakage’), while the other (usually mannitol) passes by
paracellular and transcellular transport. The urinary lactu-
lose/mannitol ratio is used as a measure of intestinal
integrity and permeability (van Elburg et al., 1995). In
addition, a recent study found a high prevalence of con-
genital GI anomalies (adjusted odds ratio 5.1, 95% conﬁ-
dence interval 1.8–14.1), notably pyloric stenosis, in
autism, which may be linked to the high rate of GI dys-
function reported by their parents (Wier, Yoshida, Odouli,
Grether, & Croen, 2006).
The implication of the GI tract in autistic pathophysi-
ology warrants more detailed investigation of the gut-brain
axis (Erickson et al., 2005). Especially the role of serotonin
(5-hydroxytryptamine; 5-HT), as a messenger within this
axis (Gershon, 2005), deserves attention. Many different
aspects of the 5-HT system in autism have already been
studied (Burgess, Sweeten, McMahon, & Fujinami, 2006;
Croonenberghs, Verkerk, Scharpe, Deboutte, & Maes,
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DOI 10.1007/s10803-007-0399-82005; Janusonis, 2005; Mulder et al., 2004). A recent re-
port (Mulder et al., 2004) on platelet (PLT) 5-HT in PDD
showed PLT hyperserotonemia in approximately 36% of
patients with autism and in 58% of patients with PDD not
otherwise speciﬁed (NOS). Using mixture-modeling anal-
ysis Mulder et al. (2004) derived an empirical cut-off value
that enabled dichotomization of patients with PDD into
normo- and hyperserotonemic. Extensive behavioral
assessments did, however, not show signiﬁcant correlates
with PLT 5-HT or hyperserotonemic status.
A common (developmental) factor, causing both an
autistic brain and deregulated 5-HT release from the GI
tract, years after birth, may be involved in the etiology of
PDD (Janusonis, 2005). The primary site of the hyperse-
rotonemia in autism is likely to be located in the GI tract.
Serotonin is a biogenic amine that derives from the
essential amino acid tryptophan (Tryp) by hydroxylation
and subsequent decarboxylation. The GI tract contains
about 80% of bodily 5-HT, which is unevenly distributed
among the enterochromafﬁn cells (90–95%) and neurons
(5–10%) (Houghton, Atkinson, Whitaker, Whorwell, &
Rimmer, 2003). The main functions of 5-HT are in smooth
muscle contraction, blood pressure regulation, and
peripheral and central neurotransmission. Serotonin local-
ized in the basolateral stores of enterochromafﬁn tissue is
released upon neuronal, chemical or mechanical stimula-
tion. Several 5-HT receptors control GI motility, sensation
and secretion (Gershon, 2005). Following its release, 5-HT
is removed from the interstitial space by 5-HT selective
reuptake transporters (Gershon, 2005). However, part of
the 5-HT enters the portal blood and systemic circulation
where it is either rapidly taken up and accumulated by
PLT, or metabolized by the liver, lung and kidneys into its
major metabolite 5-hydroxyindoleacetic acid (5-HIAA)
(Houghton et al., 2003). Platelets store and transport the
majority (99%) of circulating 5-HT (Ortiz, Artigas, &
Gelpi, 1988).
Elevated PLT 5-HT levels observed in subgroups of
patients with PDD, may be related to increased GI motility.
This notion is supported by higher PLT 5-HT in patients
with diarrhea predominant irritable bowel syndrome (d-
IBS), as compared with healthy controls (Houghton et al.,
2003), although this was not consistently found (Atkinson,
Lockhart, Whorwell, Keevil, & Houghton, 2006). Patients
with d-IBS have augmented GI motility, which is likely to
cause increased exposure of their circulating PLT to 5-HT
(Atkinson et al., 2006; Gershon, 2005; Houghton et al.,
2003). Increased PLT 5-HT is also observed in patients
with carcinoid tumors (Kema et al., 2001). Carcinoid tu-
mors derive from enterochromafﬁn cells and are charac-
terized by high 5-HT production with diarrhea as a frequent
symptom (Modlin, Kidd, Latich, Zikusoka, & Shapiro,
2005). Consequently, measurement of PLT 5-HT is used as
a sensitive marker for the early diagnosis and the
subsequent follow-up of patients with carcinoid tumors
(Kema et al., 2001).
The aim of the present study was to investigate whether
the subgroup of children with PDD having increased PLT
5-HT levels, is the same as the one exhibiting increased
intestinal permeability as established by a SAT.
Methods
Patients
Parents of patients with PDD (n = 31) according to the
DSM-IV TR (American Psychiatric Association, 1994)
were asked for the participation of their affected children
via the local patient society and pediatricians. Oral and
written informed consent were obtained. Information
regarding comorbidity, medication, nutritional supplements
and the prevalence of GI related complaints was obtained
from medical records and with the aid of assisted ques-
tionnaires. The study was performed in Curac ¸ao (The
Netherlands Antilles) in the summer of 2004. All collected
urine and blood samples were transported in dry ice to the
Netherlands for further analyses in the University Medical
Center Groningen (UMCG). The study was approved by
the Medical Ethical Committee of the St. Elisabeth Hos-
pital in Curac ¸ao.
Sugar Absorption Test
The SAT was performed according to van Elburg et al.
(1995). Shortly, the patients ingested a sugar (lactulose,
mannitol and sucrose) containing test ﬂuid after an over-
night fast. All urine voidings during the following 5 h were
collected and pooled. Urinary sugars were analyzed by gas
chromatography as previously described (Jansen, Muskiet,
Schierbeek, Berger, & van der Slik, 1986). A urinary lac-
tulose/mannitol (L/M) ratio above 0.090 was considered to
be indicative for abnormal GI integrity/increased intestinal
permeability (van Elburg et al., 1995).
Serotonin Assays
For estimation of 5-HT turnover and exposure of PLT to 5-
HT, we examined 24 h urinary excretion of 5-HIAA and
total 5-HT (Kema et al., 2001). For this, parents were
asked to abstain their child completely from 5-HT con-
taining foods (e.g. banana, pineapple, kiwi, walnuts) during
collection and during the preceding 12 h. The volumes of
the urine samples were measured before storing at –20 C.
Urinary 5-HIAA and total 5-HT concentrations were
determined as previously reported (Kema et al., 2001).
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dependent reference values (American Association for
Clinical Chemistry, 2005).
Non-fasting venous blood (for serum antibodies) and
EDTA-anticoagulated blood (all other assays) were col-
lected from children with PDD. EDTA-anticoagulated
blood was placed on melting ice. Hematological indices
were measured immediately after sampling. Within 1 h
after collection a 1:1 mixture of K2EDTA and Na2S2O5 was
added to PLT-rich plasma (PRP) to prevent oxidation of
indoles. Plasma and serum were stored at –80 C. Simulta-
neous analysis of indoles [Tryp, 5-hydroxytryptophan
(5-HTP), 5-HT and 5-HIAA] in PRP was performed as
previously described (Kema et al., 2001). PLT 5-HT data
were compared with both a local cut-off value of 5.4 nmol/
10
9 PLT (Meijer, Kema, Volmer, Willemse, & de Vries,
2000) and an empiric cut-off value of 4.55 nmol/10
9 PLT
(Mulder et al., 2004). The local cut-off value represents the
97.5th percentile of a reference group of healthy adults, that
is employed in our laboratory for the diagnosis of carcinoid
tumors. The empirical cut-off value represents the bottom
of the valley of the PLT 5-HT bimodal distribution, as
exhibited by patients with PDD. This value allows optimal
classiﬁcation into those who are normoserotonemic and
hyperserotonemic. Platelet-rich-plasma Tryp data were
evaluated with the use of age-dependent reference values
(American Association for Clinical Chemistry, 2005).
Exclusion of Celiac Disease
Serum IgA anti-endomysium titers and HLA genotype
were assessed to rule-out celiac disease, which is an
established cause of increased GI permeability (van Elburg,
Uil, Mulder, & Heymans, 1993).
Statistics
All data were analyzed using the Statistical Product and
Service Solutions package, version 11.5 (SPSS Inc. Chi-
cago). Data were tested for normality using the Shapiro–
Wilk W test. Group comparisons (normo- and hypersero-
tonemic) were performed with the Mann–Whitney U test
(non-parametric). Spearman (non-parametric) tests were
used to evaluate correlations at a = 0.05, to minimize
type-II errors.
Results
Patients
We enrolled the ﬁrst 24 (77%) of the 31 patients with PDD
whose parents agreed to participate. Patient characteristics
are reported in Table 1. The parents reported 13/23 (57%)
of their affected children to have one or more GI symp-
toms.
Because of cleanliness problems, no urine samples
were obtained from one patient, while from another we
only received urine for SAT. Blood sampling from yet
another patient was problematic. Consequently, our
study comprised urine for SAT from 23/24 patients,
24 h urine from 22/24 patients and blood samples
from 23/24 patients. Table 2 shows the indices related to
5-HT turnover and intestinal permeability of these
patients.
Sugar Absorption Test
Intestinal permeability, reﬂected by the L/M ratio [median
(range) 0.017 mol/mol (0.008–0.035)], indicated that none
of the patients had increased intestinal permeability (i.e. L/
M ratio ‡ 0.090).
Table 1 Characteristics of patients with pervasive developmental
disorders in Curac ¸ao tested for platelet serotonin and intestinal per-
meability
Parameter
Gender (male/female) 18 (75%) / 6 (25%)
Age (years) 9.9 (±3.9)
DSM-IV TR diagnoses
299.00 (autistic disorder) 8 (33%)
299.80 (PDD-NOS) 16 (67%)
Ethnicity
Caucasian 8 (33%)
African–American 13 (54%)
Other 3 (13%)
Comorbidity
Epilepsy 5 (22%)
Allergy 2 (9%)
Asthma 1 (4%)
Intestinal yeast infection 1 (4%)
Medication for comorbidity 9 (38%)
Nutritional supplements (vitamins/x3-oils) 9 (38%) / 2 (4%)
Diet (gluten and casein free)
a 2 (9%)
Physical complaints related to GI tract
a 13 (57%)
Nausea 0 (0%)
Vomiting 1 (4%)
Diarrhea 4 (17%)
Constipation 4 (17%)
Bloating and gaseousness 8 (35%)
a n = 23. PDD-NOS pervasive developmental disorder—not other-
wise speciﬁed
Data represent number (percentage) or mean (±SD) for 24 patients,
unless otherwise speciﬁed
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PLT 5-HT [median (range): 3.4 (2.0–7.1) nmol/10
9 PLT]
was elevated in 4 (range: 5.7–7.1 nmol/10
9 PLT) and 6
[range 4.6–7.1 nmol/10
9 PLT] patients if compared to
the local cut-off value ((Meijer et al., 2000); <5.4 nmol/
10
9 PLT) or the empirical cut-off value ((Mulder et al.,
2004); <4.55 nmol/10
9 PLT), respectively. The sole pa-
tient exhibiting detectable levels of plasma 5-HIAA
(26.0 lmol/l), also exhibited increased PLT 5-HT
(6.4 nmol/10
9 PLT). However, this patient did not
exhibit increased urinary total 5-HT or 5-HIAA excre-
tions. Urinary excretion of 5-HIAA was within normal
range.
Exclusion of Celiac Disease
None of the patients were positive for serum IgA anti
endomysium and 8/23 (35%) patients had a genotype po-
sitive for either HLA-DQ2 (n = 5) or HLA-DQ8 (n = 3).
Based on the results of serology, none of the patients
seemed to have celiac disease, although we did not perform
further tests to exclude this.
Statistics
There was no correlation between PLT 5-HT and L/M ratio
(p = .663; r = –.098). Patients exhibiting GI tract com-
plaints did not have higher PLT 5-HT, higher L/M ratios,
or higher 5-HIAA and total 5-HT 24 h urinary excretions
(p > .4). Platelet 5-HT correlated with 24 h urinary 5-
HIAA excretion (p = .034; r = .465). Also the 24 h
excretion rates of 5-HIAA and total 5-HT showed a posi-
tive correlation (p = .005; r = .580).
Discussion
In this study of children with PDD we did not observe a
relation between PLT 5-HT and intestinal permeability, as
derived from the urinary L/M ratio. The number of children
with PDD exhibiting increased PLT 5-HT was lower
compared with reports of others. For instance, the recent
study of Mulder et al. (2004) showed 23/81 (28%) of
Dutch children with PDD to exhibit increased PLT 5-HT,
using the same analytical method and a cut-off value of
5.4 nmol/10
9 PLT. Also our data on intestinal permeability
Table 2 Indices of serotonin (5-HT) turnover and intestinal permeability in patients with pervasive developmental disorders in Curac ¸ao
Parameter Reference values <RV ‡RV
PLT 5-HT (nmol/10
9 PLT)
a 3.4 (2.0–7.1) <4.55
b 6 (26%)
<5.4
c 4 (17%)
Tryp (lmol/l)
a 50.0 (±10.9) 2–18y: 0–79
d 0 (0%) 0 (0%)
2y: 35–73
d
6y: 37–76
d 3 (13%) 0 (0%)
16y: 54–93
d
5-HIAA (lmol/24 h)
e 8.4 (3.9–36.4) 3–8y: 2.1–29.3
d
9–12y: 5.2–32.9
d
1 (5%)
1 (5%)
13–17: 4.7–34.0
d
>18y: 5.2–36.6
d
5-HT (nmol/24 h)
e 305 (±92)
Lactulose (mmol/5 h)
f 0.024 (±0.11)
Mannitol (mmol/5 h)
f 1.32 (±0.59)
L/M ratio (mol/mol)
f 0.019 (±0.007) <0.090
g 23 (100%) 0 (0%)
a Platelet-rich plasma, n =2 3
b Empiric cut-off derived from Mulder et al. (2004)
c Upper reference value derived from apparently healthy adults Meijer et al. (2000)
d From reference American Association for Clinical Chemistry (2005)
e About 24 h urine, n =2 2
f About 5 h urine from sugar absorption test, n =2 3
g From reference van Elburg et al. (1995)
Data represent number (percentage), median (range) or mean (±SD).
RV; reference value; PLT, platelet; Tryp, tryptophan; 5-HIAA, 5-hydroxyindoleacetic acid; L/M, lactulose/mannitol
 
9
=
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123contrast with previous reports (D’Eufemia et al., 1996;
Horvath et al., 2002) showing that 43–76% of children
with autism have increased intestinal permeability, as
established by a SAT. A weakness of the current study is its
small size and the lack of a local age- and gender matched
control group. We have, on the other hand, no indications
for deviant reference values for PLT 5-HT or L/M ratios in
Curac ¸ao, as compared with The Netherlands. Age and
gender do not appear to affect PLT 5-HT (Mulder et al.,
2004), but it must be noted that PLT 5-HT reaches highest
levels during childhood and gradually decreases during
adulthood (Flachaire et al., 1990). Dependent on the cut-
off values employed, we nevertheless found 4 and 6 pa-
tients with increased PLT 5-HT. Neither of these patients
had abnormal intestinal permeability or L/M ratios residing
in the upper range of normality. However, the positive
correlation between PLT 5-HT levels and 24 h urine 5-
HIAA, and also the relation between urinary 5-HIAA and
urinary 5-HT, suggest that, also in PDD, exposure of PLT
to 5-HT determines PLT 5-HT and its consistently found
increase in a subgroup. It is possible that increased PLT 5-
HT and GI permeability are not consistent features of
children with PDD in time. Long term, e.g. monthly,
monitoring of a well deﬁned patient and control group may
shed more light on this potential source of variance as a
cause of the conﬂicting results found by several investi-
gators. Differences in the activity of the 5-HT transporter
based on genetic polymorphisms are unlikely, since these
seem to have minor effects, if any, on PLT 5-HT levels
(Mulder, 2006).
In conclusion, the ﬁnding of a subgroup of children
with PDD exhibiting hyperserotonemia was replicated.
None of the children exhibited increased intestinal per-
meability, while PLT 5-HT was unrelated to both intestinal
permeability and GI symptoms. Additional studies are
needed to elucidate the etiology of increased PLT 5-HT in
PDD and to establish its relation with intestinal pathology,
if any.
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